No headlines found.
Globe Newswire (Wed, 17-Jul 7:25 AM ET)
Globe Newswire (Mon, 15-Jul 7:30 AM ET)
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company's major business is research and development and operates only in one single segment.
Aslan Pharmaceuticals Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ASLN.
As of September 18, 2024, ASLN stock price was flat at $0.60 with million shares trading.
ASLN has a beta of 2.60, meaning it tends to be more sensitive to market movements. ASLN has a correlation of 0.03 to the broad based SPY ETF.
ASLN has a market cap of $1.70 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ASLN stock traded as high as $671.98 and as low as $.48.
ASLN has underperformed the market in the last year with a price return of -96.2% while the SPY ETF gained +27.8%. ASLN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -79.2% and 0.0%, respectively, while the SPY returned +2.9% and +1.7%, respectively.
ASLN support price is $.60 and resistance is $.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASLN stock will trade within this expected range on the day.